Anebulo Pharmaceuticals, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE15-12GAnebulo Pharmaceuticals, Inc.ANEBMar 2

   Deregistration notice

2. ROUTINE25Anebulo Pharmaceuticals, Inc.ANEBFeb 17

   Form 25 filing

3. ROUTINESCHEDULE 13G/AAnebulo Pharmaceuticals, Inc.ANEBFeb 13

   Ownership stake disclosure by Nantahala Capital Management, LLC (amended)

   Nantahala Capital Management, LLC, filed by

4. NOTABLE10-QAnebulo Pharmaceuticals, Inc.ANEBFeb 12

   Quarterly report

5. ROUTINE8-KAnebulo Pharmaceuticals, Inc.ANEBFeb 12

   Current report

6. ROUTINE8-KAnebulo Pharmaceuticals, Inc.ANEBFeb 6

   Current report

7. ROUTINESC TO-I/AAnebulo Pharmaceuticals, Inc.ANEBJan 29

   Issuer tender offer (amended)

8. ROUTINE8-KAnebulo Pharmaceuticals, Inc.ANEBJan 29

   Current report

9. ROUTINESC TO-I/AAnebulo Pharmaceuticals, Inc.ANEBJan 27

   Issuer tender offer (amended)

10. ROUTINE8-KAnebulo Pharmaceuticals, Inc.ANEBJan 27

    Current report

11. ROUTINESC TO-I/AAnebulo Pharmaceuticals, Inc.ANEBJan 8

    Issuer tender offer (amended)

12. ROUTINESC TO-IAnebulo Pharmaceuticals, Inc.ANEBDec 22, 2025

    Issuer tender offer

13. ROUTINESC TO-IAnebulo Pharmaceuticals, Inc.ANEBDec 22, 2025

    Issuer tender offer

14. ROUTINE8-KAnebulo Pharmaceuticals, Inc.ANEBDec 22, 2025

    Current report

15. NOTABLE10-QAnebulo Pharmaceuticals, Inc.ANEBNov 13, 2025

    Anebulo Pharmaceuticals, Inc. (ANEB) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities.

16. MAJOR8-KAnebulo Pharmaceuticals, Inc.ANEBNov 13, 2025

    Anebulo Pharmaceuticals, Inc. (ANEB) announced the resignation of its Chief Financial Officer, effective immediately. This unexpected leadership change could impact the company's financial reporting and operations, and investors should closely monitor any updates regarding the…

Older filings on EDGAR